Bioventus completed a $15m investment in CartiHeal.

Bioventus, which develops and markets orthopedic therapies and diagnostic tools, completed a $15m investment in CartiHeal, an Israel-based developer of the proprietary Agili™-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. "We are pleased Bioventus continues to see value in the Agili-C implant and is making a greater investment to support the completion of the IDE study. We look forward to the work ahead and a successful application for PMA approval," Nir Altschuler, CartiHeal Founder and CEO.